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Protein kinase A is a key mediator of cAMP signalling downstream of G protein coupled receptors, 
a signalling pathway conserved in all eukaryotes. cAMP binding to the regulatory subunits (PKAR) 
relieves their inhibition of the catalytic subunits (PKAC). Here, we report that ARHGAP36 combines 
two distinct inhibitory mechanisms to antagonise PKA signalling. Firstly, it blocks PKAC activity via 
a pseudosubstrate motif, akin to the mechanism employed by the protein kinase inhibitor 
proteins. Secondly, it targets PKAC for rapid ubiquitin-mediated lysosomal degradation, a pathway 
usually reserved for transmembrane receptors. ARHGAP36 thus dampens the sensitivity of cells to 
cAMP. We show that PKA inhibition by ARHGAP36 promotes derepression of the Hedgehog 
signalling pathway, thereby providing a simple rationale for the upregulation of ARHGAP36 in 
medulloblastoma. Our work reveals a new layer of PKA regulation that may play an important role 
in development and disease. 
 
 
 
 
 
 
 
 
 
 
2 
 
 
PKA is a widely expressed serine/threonine kinase regulating essential cellular processes important in 
development, metabolism, memory formation and proliferation1. The inactive tetrameric 
holoenzyme comprises a dimer of regulatory subunits (PKAR), each of which binds a catalytic subunit 
(PKAC) in its active-site cleft, thereby blocking kinase activity and access to substrates. PKA activation 
occurs upon binding of cAMP to PKAR, causing the release of PKAC and thus allowing 
phosphorylation of numerous downstream proteins. Misregulated PKA signalling is linked to various 
human diseases and recent studies have identified pathway activating mutations in both PKAR and 
PKAC as well as in other upstream components in a number of cancers2-8. Since PKA regulates a 
myriad of cellular responses, precise spatio-temporal control is required to ensure its signalling 
specificity. A-kinase anchoring proteins (AKAPs) bind PKAR and target the holoenzyme to distinct 
subcellular compartments. AKAPs serve as scaffolds to place PKA in the vicinity of specific substrates 
together with phosphodiesterases, phosphatases or components of wider signalling networks, 
thereby providing tailored cAMP signalling units9,10. In addition, PKA activity can be negatively 
regulated by a family of small, heat-stable protein kinase inhibitor (PKI) proteins, each containing a 
pseudosubstrate motif by which they bind PKAC with high affinity11. On the other hand, cAMP-
dependent proteasomal degradation of PKAR can positively modulate PKA activity by increasing the 
pool of free PKAC. This mechanism facilitates long-term memory formation12 and involves the E3 
ubiquitin ligase Praja213. Ubiquitin-mediated degradation of PKAC has so far not been described, 
although regulated proteolysis is a common mechanism for downregulating activated protein 
kinases14,15.  
Here we report the identification of the Rho GTPase activating protein (RhoGAP) family member 
ARHGAP36 as a potent antagonist of PKA signalling. ARHGAP36 is not only a PKA pseudosubstrate 
inhibitor but also targets PKAC for ubiquitin-dependent proteolysis. Unexpectedly for a cytosolic 
protein, PKAC degradation is not mediated by the proteasome but by the endolysosomal system. This 
pathway typically mediates degradation of activated receptor tyrosine kinases16,17. ARHGAP36 has 
previously been shown to activate the Hedgehog signalling pathway and is upregulated in a subset of 
medulloblastoma, suggesting an important role in tumourigenesis18. PKA is a master negative 
regulator of the Hh pathway 19,20, therefore PKA inhibition by ARHGAP36 provides a straightforward 
mechanism for this observation. Our study thus defines a new paradigm for negative PKA regulation 
with implications in health and disease. 
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RESULTS 
ARHGAP36 interacts with PKAC 
In a systematic mass spectrometric analysis of the Rho GTPase regulatory proteins we identified 
ARHGAP36 as a new binding partner of PKAC (O. Rocks, T. Pawson et al, unpublished observation). 
ARHGAP36 has five annotated isoforms with molecular masses between 46 and 61 kDa, which vary 
only in their extreme N-terminal portion. All contain an arginine rich region followed by a RhoGAP 
domain (Fig. 1a and Supplementary Figure S1).   
To further investigate this interaction, we first confirmed the association of overexpressed 
ARHGAP36 both with ectopic and endogenous PKAC by co-immunoprecipitation (Fig. 1b). In MDCK 
cells, ARHGAP36 expressed alone was concentrated at the plasma membrane while PKAC appeared 
largely cytosolic. However, upon coexpression PKAC was completely recruited by ARHGAP36, with 
both proteins exhibiting a pronounced colocalisation on vesicles (Fig. 1c). We further analysed the 
interaction by fluorescence lifetime imaging microscopy based fluorescence resonance energy 
transfer (FLIM-FRET)21. A PKAC-YFP donor and mCherry-ARHGAP36 acceptor fluorophore exhibited 
substantial FRET as apparent from the decreased donor fluorescence lifetime (Fig. 1d). Acceptor 
photobleaching restored the long-lived donor lifetime, confirming the direct interaction of 
ARHGAP36 and PKAC.  
 
ARHGAP36 binds PKAC via an N-terminal pseudosubstrate motif 
We mapped the interaction site with PKAC to the N-terminus of ARHGAP36. Its deletion rendered 
ARHGAP36 cytosolic and abolished the interaction with PKAC (Fig. 2a, 2b, 2g and Supplementary Fig. 
S2a). The N-terminus and furthermore, just 77 amino acids (118-194 ‘N2’) containing the arginine 
rich region were sufficient both for interaction and colocalisation of ARHGAP36 and PKAC. Peptide 
spot experiments pinpointed the interaction site to a 25 amino acid sequence (Fig. 2c). Subsequent 
alanine and aspartate scanning of this sequence revealed the requirement of two arginines 
R153/R154 for PKAC binding (Fig. 2d). We noticed that the sequence adjacent to the arginines 
(RRGAV) matches the consensus motif (R-R-X-S/(A/G)-Y) for PKAC substrates/inhibitors, where X is 
variable, Y a hydrophobic residue and S/(A/G) the phosphorylation/pseudophosphorylation site, 
respectively1,22 (Fig. 2e). This motif, shared by all PKAR subunits and PKIs, docks into the acidic active 
site cleft of PKAC1,23. Aspartate mutation of three residues R153D/R154D/V157D (RRV) within this 
site impaired the colocalisation and interaction of ARHGAP36 with PKAC (Fig. 2f and 2g, 
Supplementary Fig. S2b and S2c). Likewise, substitution of three corresponding glutamate residues 
E127A/E170A/E230A (EEE) in the acidic active site cleft of PKAC, shown to ion-pair with the 
pseudosubstrate motif arginines of PKAR24, compromised the interaction of PKAC with ARHGAP36 
(Fig. 2g, Supplementary Fig. S2d, S2e and S2f). Using isothermal titration calorimetry (ITC), we found 
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that a synthesised peptide comprising the 25 amino acid ARHGAP36 pseudosubstrate motif (36i, Fig. 
2c) bound with high nanomolar affinity to purified PKAC in the presence of the non-hydrolysable ATP 
analogue adenylyl-imidodiphosphate (AMPPNP) (Fig. 2h, Supplementary Fig. S2g, S2h). A similar 
value was obtained with a PKI (5-24) derived peptide, supporting our notion of related binding 
modes for these two peptides. These experiments demonstrate the direct interaction between 
ARHGAP36 and PKAC, mediated by a pseudosubstrate motif on ARHGAP36. 
 
ARHGAP36 inhibits PKAC catalytic activity 
As ARHGAP36 and PKAR share the same binding site on PKAC, we next investigated whether 
ARHGAP36 also inhibits the catalytic activity of PKAC, similar to the mode of PKAC inhibition by PKI25. 
Firstly, we performed an in vitro kinase assay with recombinant PKAC. Addition of 36i peptide 
strongly reduced the fraction of phosphorylated PKA substrate (Fig. 3a). A similar extent of kinase 
inhibition was achieved with equal concentrations of PKI (5-24) peptide. We further analysed the 
impact of ARHGAP36 on PKA activity in cells using a genetically encoded FRET-based PKA biosensor 
(AKAR4-NES)26. Coexpression of full-length ARHGAP36 with AKAR4-NES caused a strong decrease in 
PKA activity in stimulated cells, as evident from the reduction in mean FRET emission ratio (25.7 ± 0.9 
%, Fig. 3b and 3c). ARHGAP36-N or ARHGAP36-RRV did not alter PKA activity levels, whereas 
ARHGAP36-N2, containing the pseudosubstrate site, decreased PKA activity to the same extent as 
the full-length form (25.1 ± 1.0 %). Constructs encoding 36i, or full length PKI, also significantly 
reduced PKA activity (by 28.4 ± 0.2 % and 25.9 ± 1.0 %, respectively). The above experiments 
collectively demonstrate that ARHGAP36 is a pseudosubstrate inhibitor of PKAC with potency 
comparable to PKI. 
 
ARHGAP36 causes depletion of PKAC 
We consistently noticed a dramatic downregulation of endogenous PKAC upon ARHGAP36 
expression (see Fig. 1b) and therefore wondered whether ARHGAP36 also controlled PKAC stability. 
Protein levels of endogenous PKAC in YFP-ARHGAP36 expressing MDCK cells were already markedly 
reduced just eight hours after transfection, with the two proteins colocalising on vesicles (Fig. 4a). 
After 24 hours of ARHGAP36 transfection, PKAC was almost completely depleted. Downregulation of 
endogenous PKAC could also be seen in HEK293T cells overexpressing ARHGAP36 (Fig. 4b). PKAC 
depletion is not secondary to an effect on PKAR: ARHGAP36 overexpression did not affect protein 
levels of PKAR isoforms in either HEK293T or MDCK cells (Fig. 4c and Supplementary Fig. S3a). We 
then asked whether the simple displacement of PKAC from PKAR, by competitive binding of a 
pseudosubstrate, is sufficient to promote its downregulation. However, expression of full length PKI 
did not affect endogenous PKAC protein levels, suggesting the ability to downregulate PKAC is a 
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specific feature of ARHGAP36 (Fig. 4d and Supplementary Fig. S3b). Direct interaction with 
ARHGAP36 is required for PKAC downregulation as expression of ARHGAP36-N or ARHGAP36-RRV 
failed to deplete endogenous PKAC. 36i, encoding only the pseudosubstrate motif, was equally 
without effect, whilst ARHGAP36-N and ARHGAP36-N2 promoted efficient depletion of PKAC (Fig. 4e 
and Supplementary Fig. S3b). Pseudosubstrate binding is thus necessary but not sufficient to 
promote a decrease in PKAC levels. The RRGAV binding motif on ARHGAP36 mediates the interaction 
with PKAC, while the downregulatory properties are encoded nearby.   
 
ARHGAP36 targets PKAC for lysosomal degradation 
We wondered which of the main cellular protein degradation pathways, the proteasomal or the 
endolysosomal system, were responsible for PKAC downregulation in ARHGAP36 transfected cells. 
We therefore treated cells with the protein synthesis inhibitor cycloheximide (CHX) and analysed 
PKAC protein levels in the presence of inhibitors against these pathways. Surprisingly, we saw no 
effect with the proteasome inhibitor epoxomicin (Fig. 5a and Supplementary Fig. S4). Instead, PKAC 
levels were partially rescued by treatment with bafilomycin, which blocks the acidification of the 
endolysosomal compartment27. Similarly, in MDCK cells, CHX treatment caused a loss of endogenous 
PKAC that could not be rescued by epoxomicin (Fig. 5b). In contrast, addition of bafilomycin resulted 
in a build-up of PKAC together with ARHGAP36 on enlarged vesicles. In the presence of YFP-
ARHGAP36, endogenous PKAC colocalised with the coexpressed early endosomal/multivesicular 
body (MVB) marker HRS and the late endosomal/lysosomal marker LAMP1 (Fig. 5c). Coexpressed 
ARHGAP36 and PKAC also colocalised with the endogenous early endosome marker EEA1 and HRS 
(Fig. 5d). Moreover, when we coexpressed ARHGAP36 with constitutively active Rab5 Q79L to induce 
enlarged endosomes and thus to facilitate resolution of the MVB lumen from the surrounding 
limiting membrane28, we clearly observed endogenous PKAC inside these vesicles (Fig. 5c). These 
experiments show that ARHGAP36 targets PKAC, a cytosolic protein, for lysosomal degradation. 
 
ARHGAP36 induces PKAC ubiquitylation and engagement with the ESCRT pathway  
As ubiquitin is the key sorting signal for lysosomally directed cargos, we investigated if this 
modification is required for ARHGAP36-dependent PKAC downregulation. Expressed on its own, 
PKAC-YFP is only minimally ubiquitylated. However, coexpression of Flag-ARHGAP36 strongly induced 
the appearance of higher molecular weight ubiquitylated species (Fig. 6a). Using SILAC-based mass 
spectrometry, we identified a single ubiquitylation site on PKAC, K285, that was specifically regulated 
by ARHGAP36 (Fig. 6b, Supplementary Fig. 5a, S5b and Supplementary Table1). Substitution to 
arginine, K285R, prevented ARHGAP36 induced polyubiquitylation and stabilised this mutant, whilst 
binding to ARHGAP36 was unaffected (Fig. 6c and 6d). A direct interaction with ARHGAP36 was 
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essential for PKAC ubiquitylation, as the binding-deficient ARHGAP36-RRV mutant no longer induced 
ubiquitylation (Fig. 6e). CHX chase experiments revealed that both wild-type and K285R PKAC were 
stable for at least nine hours in the absence of ARHGAP36 (Supplementary Fig. S5c), in agreement 
with previous data29. However, in the presence of ARHGAP36, the protein half-life of wild-type PKAC 
was shorter than three hours, whereas the K285R mutant remained stable throughout. The 
degradation of wild-type PKAC could be rescued by bafilomycin, or the lysosomal protease inhibitor 
leupeptin, causing accumulation of PKAC on vesicles, whereas the K285R mutant was always stable 
(Fig. 6f and Supplementary Fig. S5d). These experiments demonstrate an absolute requirement of 
polyubiquitylation at K285 for ARHGAP36-mediated PKAC degradation.  
The PKAC ubiquitylation pattern presented consistently with distinct high molecular weight bands 
(see Fig. 5c and 5d for example). While K48-polyubiquitylation typically targets proteins to the 
proteasome, K63-linked polyubiquitin chains are implicated in lysosomal degradation and binding to 
ESCRT-0 (Endosomal Sorting Complex Required for Transport)30-33. Selected Reaction Monitoring 
(SRM) mass spectrometry34 identified a strong build up in K63- but not K48-linked ubiquitin chains 
associated with immunoprecipited PKAC upon coexpression of ARHGAP36 (Fig. 6g). We also 
employed the UbICREST assay35, which makes use of deubiquitylase (DUB) cleavage specificity to 
identify chain linkages. We consistently detected partial cleavage by AMSH, a highly selective K63-
linked ubiquitin chain editing endosomal DUB36, resulting in the accumulation of an additional lower 
molecular weight species corresponding to the expected end-product of this reaction: mono-
ubiquitylated PKAC. In contrast, the K48-linkage specific DUB OTUB1 was without effect, whilst the 
whole ubiquitin-smear was readily removed by the linkage insensitive DUB USP2 (Supplementary Fig. 
S5e). These data indicate the involvement of K63-linked ubiquitin, and further support a model in 
which ARHGAP36 targets PKAC for lysosomal degradation.   
Lysosomal targeting of ubiquitylated cargo relies on the ESCRT protein complexes. To test their 
involvement, we used a dominant negative form of Vps4, an AAA-ATPase that is required for the 
recycling of ESCRT-components and pinching off of intraluminal vesicles at a late step in the sorting 
mechanism37,38. Expression of wild-type Vps4 had no effect on ARHGAP36-induced PKAC 
degradation. However, overexpression of the dominant negative E228Q mutant of Vps4 was able to 
rescue ARHGAP36-induced PKAC degradation, suggesting this process is mediated by the ESCRT-
machinery (Fig. 6h). In summary, we conclude that ARHGAP36 targets PKAC for ubiquitin-dependent, 
ESCRT-mediated lysosomal degradation, a pathway usually reserved for membrane proteins.  
 
ARHGAP36 suppresses PKA signalling and promotes aberrant activation of the Hedgehog pathway 
The above data suggest that ARHGAP36 strongly interferes with PKA signalling. Initiation of gene 
transcription upon phosphorylation of the transcription factor CREB (cAMP response element binding 
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protein) is a well-characterised PKA-induced cellular response. Forskolin/IBMX stimulation of MDCK 
cells promoted phospho-CREB accumulation in cell nuclei (Fig. 7a and Supplementary Fig. S6a). In 
contrast, in YFP-ARHGAP36 expressing cells, stimulation-dependent CREB phosphorylation was 
blocked. 36i expression also blocked CREB phosphorylation, as did full length PKI, whereas 
ARHGAP36-RRV, the pseudosubstrate mutant, was ineffective (Fig. 7b and Supplementary Fig. S6b). 
As a second example of a PKA-dependent cellular process, we monitored the trafficking of the water 
channel aquaporin-2 (AQP2). In unstimulated kidney collecting duct cells, AQP2 localises on vesicles. 
Upon cAMP-elevation AQP2 translocates to the plasma membrane, where it fine-tunes water 
homeostasis39. MCD4 mouse collecting duct cells, stably expressing human AQP2, were transfected 
with YFP-ARHGAP36 or YFP control. Without stimulation, AQP2 was located on vesicles 
(Supplementary Fig. S6c). Upon Forskolin stimulation, AQP2 translocated to the plasma membrane in 
control cells, whereas in YFP-ARHGAP36 transfected cells, AQP2 was retained on cytoplasmic vesicles 
(Fig. 7c). The above experiments show that PKA signalling is repressed in the presence of ARHGAP36.  
 
Next, we investigated whether ARHGAP36 also antagonises PKA in an endogenous setting. As we 
observed such a strong impact on PKA, we first wondered whether ARHGAP36 expression may be 
regulated during development or restricted to certain tissues. Indeed, mouse in situ hybridisation 
revealed that Arhgap36 is strongly expressed in skeletal muscle fibres during embryogenesis right up 
until birth, but is undetectable in postnatal muscles (Supplementary Fig. S7). This restricted tissue 
expression may explain the absence of ARHGAP36 in commonly used cell lines (Fig. 8a). However, 
expression databases suggested ARHGAP36 is expressed in neuroblastoma cell lines 
(www.nextbio.com) and we indeed identified its expression at comparable levels in NGP and CLB-GA 
cells40,41, where endogenous ARHGAP36 localised similarly to the overexpressed protein (Fig. 8a, 
Supplementary Fig. S8a-c). Intensity based absolute quantification (iBAQ) mass spectrometry29 in 
NGP cells showed that ARHGAP36 and PKAC are expressed at approximately equimolar levels (Fig. 8b 
and Supplementary Fig. S8d). Furthermore, we could confirm that endogenous ARHGAP36 interacts 
with endogenous PKAC (Fig. 8c) and demonstrate that both proteins colocalise together on the 
limiting membrane as well as inside Rab5 Q79L enlarged endosomes (Fig. 8d). Importantly, acute 
knockdown of ARHGAP36 by RNAi led to a significant increase in PKAC levels in both cell lines, and, in 
NGP cells, to a concomitant increase in CREB phosphorylation (Fig. 8e,f and Supplementary Fig. 
S8e,f). Moreover, immunofluorescence microscopy revealed a striking inverse correlation of 
ARHGAP36 and PKAC levels in the NGP cell line: cells with high ARHGAP36 expression exhibited low 
PKAC levels and vice versa (Fig. 8g and Supplementary Fig. S8g), presumably reflecting the existence 
of two sub-populations of cells in this non-clonal cell line. Collectively, these experiments 
demonstrate that ARHGAP36 both inhibits and degrades PKAC in an endogenous context. 
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ARHGAP36 was recently reported to also be upregulated in a subset of medulloblastoma18, the most 
common malignant childhood brain tumour. This cancer is frequently associated with abnormal 
Hedgehog (Hh) signalling42, a key pathway controlling animal development19. ARHGAP36 was shown 
to activate Hh signalling in a Smoothened-independent manner18. However, how ARHGAP36 
promotes oncogenic Hh activation was unknown. We thus asked whether ARHGAP36 activates this 
pathway via its effects on PKA. Using NIH3T3 cells, we monitored the transcript levels of endogenous 
Gli1, a Hh target gene commonly used as a readout for pathway activity43. We first confirmed that 
these cells were responsive to Hh stimuli (Supplementary Fig. S8h) and then assessed the ability of 
different ARHGAP36 constructs to activate the Hh pathway in the absence of ligand. In agreement 
with previous data18, we observed a robust increase in Gli1 transcripts in ARHGAP36 expressing cells 
(Fig. 8h). ARHGAP36-N2, containing the pseudosubstrate motif, but not ARHGAP36-N, lacking this 
motif, also promoted Gli1 expression. Importantly, the ARHGAP36-RRV mutant that is unable to bind 
and inhibit PKAC, was without effect. We also observed a strong increase in Gli1 transcripts upon 
overexpression of PKI, showing that PKA inhibition can indeed induce the Hh pathway in a ligand-
independent manner (Fig. 8i). We conclude that ARHGAP36 promotes Hh signalling by suppressing 
PKAC, underpinning the role of PKA as a negative regulator of the Gli proteins19,20,44. Our experiments 
thereby provide a mechanism by which aberrant ARHGAP36 expression may promote 
medulloblastoma formation. Our data raises the possibility that abnormal ARHGAP36 expression 
could contribute to further disease settings that are regulated by PKA signalling. 
 
DISCUSSION 
We here report the identification of ARHGAP36 as a potent PKA antagonist, employing two different 
inhibitory mechanisms. Peptide spot mapping, point mutagenesis, ITC and activity assays revealed 
that ARHGAP36 directly binds to PKAC via a pseudosubstrate motif by which it blocks PKA activity 
with potency comparable to the PKI proteins. In addition, it mediates the ubiquitylation of PKAC and 
targets it for endolysosomal degradation. As a consequence, PKA signalling is suppressed in the 
presence of ARHGAP36. This is the first report of ubiquitylation dependent downregulation of PKAC. 
Many other kinases are known to be subject to regulated proteolysis as an efficient means of signal 
termination14,15. To our surprise, ARHGAP36 targets PKAC not to the proteasome, the default 
pathway for the downregulation of cytosolic proteins, but for endolysosomal degradation. This 
pathway typically processes endocytosed transmembrane receptors, such as the EGFR14,15,45.  
To our knowledge, only one other cytosolic kinase, GSK3, has been reported to be incorporated into 
the endolysosomal system in an ESCRT-dependent manner46. In response to sustained Wnt stimulus, 
GSK3 is sequestered into MVBs away from its cytosolic substrates, in particular ß-catenin, which is 
otherwise constitutively turned over. However, both the mechanism by which GSK3 is targeted to 
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MVBs and its subsequent fate are unclear. In contrast to PKAC in the present study, GSK3 has not 
been reported to be ubiquitylated and thus the mechanism by which GSK3 engages with the ESCRT-
machinery remains unresolved. ARHGAP36 appears to be partially incorporated into the lumen of 
Rab5 Q79L enlarged endosomes together with PKAC. The endosomal E3 ligase and multi-subunit 
adapter protein CBL has also been seen to translocate with cargo into the internal vesicles of MVBs47. 
However, the bulk of overexpressed ARHGAP36 does not seem to be degraded, as total protein levels 
do not change, even upon CHX treatment (Fig. 6f,h and S5c,d). Whilst we have so far failed to identify 
the E3 ligase mediating PKAC ubiquitylation, we show the strict requirement of a single ubiquitylation 
site (K285) in the Vps4-dependent incorporation of PKAC into MVBs and its subsequent rapid and 
efficient degradation in lysosomes. Interestingly, GSK3 is also subject to a bimodal negative 
regulation in that its kinase activity is initially inhibited by binding to the intracellular domain of the 
LRP6 receptor upon Wnt stimulation48,49. Our work raises the question whether endolysosomal 
degradation of cytosolic signalling proteins represents a more general mechanism for effective long-
term signal termination. Entry into this pathway may be facilitated by a membrane associated 
interaction partner that can mediate access to endocytic sorting. 
In contrast to PKAC, PKAR has been shown to be degraded by the proteasome, during the 
establishment of long-term synaptic plasticity. The resultant change in R/C ratios causes persistent 
PKAC signalling that is uncoupled from cAMP-levels12,13, the spatial separation of PKAR and PKAC 
degradation may be important in such a mechanism. It is possible that PKAC is less amenable to 
unfolding by the AAA-ATPases of the proteasomal regulatory particle, which is a prerequisite for 
entry into the core particle and thus degradation50. Alternatively, ARHGAP36-mediated 
endolysosomal degradation of PKAC may provide a mechanism for timely inactivation and selective 
degradation of a restricted pool of PKAC, thus contributing to the compartmentalisation of PKA 
signalling responses. Localised regulation of PKAC may also explain why the phosphorylation status of 
the nuclear substrate CREB is unchanged upon depletion of ARHGAP36 in CLB-GA cells: in these cells 
ARHGAP36 is predominantly localised to endosomal membranes.  
ARHGAP36 further extends the repertoire of PKA regulators. Whereas modulation of PKA enzymatic 
activity is generally centred on PKAR, ARHGAP36 directly binds to PKAC and uncouples it from 
upstream control via PKAR. The dual mode PKAC inhibition by ARHGAP36, pseudosubstrate binding 
and subsequent degradation, ensures both immediate and sustained negative control of PKA. 
Dependent on the context this could operate in a constitutive fashion: ARHGAP36 may serve as a 
tonic suppressor of PKA to profoundly dampen the sensitivity of certain tissues to cAMP-releasing 
stimuli. It could also oppose basal PKA activation through cAMP-independent mechanisms in the 
absence of stimulus, particularly in settings with stoichiometric excess of free PKAC. Compensatory 
mechanisms have been proposed to balance the relative PKAR/PKAC expression levels in order to 
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preserve proper responsiveness of the PKA holoenzyme to cAMP51,52. ARHGAP36 may participate in 
such a regulation by providing additional buffering capacity.   
We observed temporally restricted expression of Arhgap36 in skeletal muscles during mouse 
embryonic development. Fittingly, expression profiling identified Arhgap36 (RIKENcDNA1100001E04) 
as a major target gene of the myogenic transcription factor MyoG53. ARHGAP36 may also antagonise 
PKA in other select tissues. It is tempting to speculate that it is expressed in contexts where 
additional safeguard mechanisms are needed to ensure tight control of PKA. Future gene targeting 
studies in mice will reveal the details of such tissue-specific PKA desensitisation and thus the role of 
ARHGAP36 in development and homeostasis.  
Since ARHGAP36 is a strong suppressor of PKA signalling, it is conceivable that aberrant ARHGAP36 
expression is implicated in disease. It will be interesting to further explore the role of ARHGAP36 and 
PKA in neuroblastoma. In human medulloblastoma, upregulated ARHGAP36 has been linked to its 
ability to activate Hh signalling in a Smoothened-independent manner18. Our work strongly suggests 
that this ARHGAP36-dependent oncogenic pathway activation is via inhibition of PKAC. ARHGAP36 is 
also found to be upregulated in human pheochromocytomas, a neuroendocrine tumor arising from 
chromaffin cells of the adrenal Medulla54. Deregulated PKA signalling due to mutations in the 
cAMP/PKA axis is associated with numerous other diseases, such as Cushing’s syndrome, 
hepatocellular carcinoma, basal-cell carcinoma, Carney Complex and McCune-Albright-syndrome2-8, 
55,56. Dependent on the signalling context in which PKA functions, aberrant ARHGAP36 expression 
could have both tumour suppressive and oncogenic roles.  
In conclusion, our data indicate that ARHGAP36-mediated PKAC inhibition and downregulation is a 
potent shutdown mechanism to efficiently suppress PKA-dependent cellular responses. This 
mechanism involves the unexpected uptake of cytosolic PKAC into the endolysosomal system for 
subsequent degradation. Our work extends the molecular map of the regulatory circuitry controlling 
the highly conserved cAMP signalling pathway and provides new insights into its dysregulation in 
human disease. 
 
 
 
METHODS 
 
Cell Lines 
Human embryonic kidney (HEK293T) cells were cultured in DMEM containing 10% FBS, and 
transfected using Polyethylenimine (PEI). Madin-Darby canine kidney II (MDCK) cells were cultured in 
MEM containing 10% FBS, and transfected using Effectene (Qiagen). MCD4 mouse collecting duct 
cells stably expressing human AQP239,57 were cultured in DMEM/F12 supplemented with 5% FBS and 
5 M dexamethasone, and transfected using PEI. NIH3T3 mouse fibroblasts and U2OS human 
11 
 
osteosarcoma cells were cultured in DMEM containing 10% FBS, and transfected using Lipofectamine 
3000. NGP and CLB-GA cells were cultured in RPMI containing 10% FBS, and transfected using 
Lipofectamine 3000. 
 
Antibodies and Chemicals  
Rabbit polyclonal antibodies against phospho-CREB, EEA1 and GAPDH were purchased from Cell 
Signaling, as well as mouse monoclonal anti-GST and anti-CREB. Flag M2, His and Tubulin DM1a 
mouse monoclonal antibodies were purchased from Sigma. PKAC, RIRII and RII mouse 
monoclonals were purchased from BD Biosciences, RIsheep was from R+D systems. Rabbit anti-GFP 
used for blotting and IPs, and chicken anti-GFP used for IF were both purchased from AbCam. The 
mouse monoclonal anti-Ubiquitin antibody P4G7 was purchased from Covance. Rabbit polyclonal 
anti-HRS and rabbit polyclonal anti-AQP2 (H27) were described previously58,59.  Monoclonal rat anti-
ZO-1 was from Santa Cruz. Rabbit anti-ARHGAP36 from Atlas Antibodies was used for IF and western 
blotting, and rabbit anti-ARHGAP36 from Thermo was used for IF and IP. Forskolin, IBMX, bafilomycin 
and epoxomicin were purchased from Cayman, Leupeptin from US Biological, cycloheximide from 
Calbiochem, SAG (Smoothened AGonist) from Enzo and CellTracker Deep Red from Thermo.  
 
Plasmids 
cDNAs for overexpression of ARHGAP36 were subcloned into plasmids of the Creator system 
described previously60. The full length sequence refers to human ARHGAP36 UniProt ID: Q6ZRI8-2.  
Subsequent mutation and deletion constructs were created by site-directed mutagenesis (Agilent 
Technologies). 36i was amplified with the following primers:  36i_N1_f 
gcgcggaattcgccaccatggagcccaccttgccccgg and 36i_N1_r cgcgcaccggtccgctcagctcagccagactatccac, or 
36i_C1_f gcgcgtgtacagcgagcccaccttgccccgg and 36i_C1_r cgcgcgaattcctacagctcagccagactatc and 
inserted into pmCherry-C1 (Clontech) with BsrGI and EcoRI, or into pmCherry-N1 (Clontech) with 
EcoRI and AgeI.  Mouse PKAC-Venus YFP was provided by Manuela Zaccolo61. Human PRKACA 
(GenBank: BC039846.1) was cloned into a C-terminal Flag-tagged gateway vector (Life Technologies). 
K286R mutants were generated by site directed mutagenesis. Human PRKAR1α (GenBank: 
BC036285) was cloned into the gateway system. Cerulean CFP-PKI was kindly provided by Susan 
Taylor (University of California, San Diego). AKAR-4-NES and PKI-Cherry were provided by Jin Zhang 
(Johns Hopkins)26,62. LAMP1-YFP was a gift from Lee Haynes (University of Liverpool). GFP-HRS was 
described previously58. GFP-Vps4 and the EQ mutant were a gift from Phil Woodman37, GFP-Rab5 
Q79L was a gift from Volker Haucke (FMP, Berlin).  
 
Lysis and Immunoprecipitation  
HEK293T cell pellets were lysed in NP40 lysis buffer (1% NP40, 20 mM Tris-HCL pH 7.5, 150 mM NaCl, 
1 mM EGTA, 5 mM NaF) with complete protease inhibitor cocktail (Roche) and N-Ethylmaleimide 
(NEM, Sigma). For IP cleared lysates were added to either Flag-M2 affinity gel (Sigma), or Protein G 
Sepharose beads (Sigma) coupled with anti-GFP (ab290, Abcam) or anti-His (Sigma). After minimum 1 
h rotation at 4˚C, beads were washed three times in lysis buffer and eluted with Laemmli buffer. NGP 
and CLB-GA cells were lysed directly in RIPA (50 mM Tris pH 7.4, 150 mM NaCl, 0.1 % SDS, 1 % NP40, 
0.5 % Sodiumdeoxycholate). For normal lysis RIPA was supplemented with complete protease 
inhibitor cocktail (Roche), NEM and PhosSTOP (Roche). For IP experiments RIPA was supplemented 
with EDTA-free complete protease inhibitor cocktail (Roche), NEM, 5 mM MgCl2 and 1 mM ADP. 4.5 
mg protein was incubated for one hour at 4 ˚C with 4 g ARHGAP36 Thermo antibody or IgG control. 
Beads were then added for 30 min, washed three times in lysis buffer and eluted with Laemmli 
buffer. 
 
siRNA knockdown 
NGP cells were cultured for two days, CLB-GA for one, before transfection with 50 nM ARHGAP36 
SMARTpool or individual oligos, or Non-Targeting oligo 1 (NT1) (Dharmacon) using Lipofectamine 
RNAiMAX (Invitrogen) according to manufacturer’s guidelines. 24 or 48 hours later cells were lysed 
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directly in RIPA. Cells were stimulated with 10 M Forskolin and 100 M IBMX for 30 min before 
harvesting. ARHGAP36 On Target Plus Oligos: J-032590-12 GCGGGUCAGCUCCGAGAAA, J-032590-11 
CCUCGGAGACGGACAUCGA, J-032590-10 UAUGAGAUUUACCGGGAUU and J-032590-09 
GCAUGCAGAGAGAGCGCUA. 
 
Immunoflourescence  
Cells seeded on glass coverslips were fixed with 4 % PFA for 10 min, permeabilised with 0.2% Triton 
X-100/ 100 mM glycine for 10 min and blocked for 20 min in 3% BSA, before primary antibody 
incubation for 1 h at room temperature or at 4 °C overnight. Alexa Fluor secondary antibodies 
(Molecular Probes) were incubated for 30 min. Coverslips were mounted using ProLong Gold 
(Invitrogen).  
 
Peptide Spots  
Peptide spots were produced by automatic SPOT synthesis on Whatman 50 cellulose membranes 
using Fmoc (9-fluorenylmethyloxycarbonyl) chemistry with the AutoSpot-Robot ResPep-SL (Intavis 
Bioanalytical Instruments) as described previously63. Fmoc-protected amino acids and derivatized 
cellulose-membranes (amino-modified acid-stable cellulose membrane with PEG-spacer) were 
purchased from Intavis. Membranes were incubated with 0.1 µg/µl GST-PKAC (Biovision) and 
interactions were detected using anti-GST, as for Western blotting.   
 
Fluorescence microscopy 
Confocal laser scanning microscopy was performed on a Fluoview 1000 confocal microscope 
(Olympus) equipped with a UPLSAPO 60X/1.3 NA silicon immersion oil immersion lens. Images were 
taken with the following excitation (Ex) and emission (Em) settings: Hoechst Ex: 405nm diode laser 
(50 mW) Em: 425-475 nm; mCerulean Ex: 440 nm diode laser (25 mW) Em: 460-500 nm; GFP, 
AlexaFluor488 Ex: Multi-Line Argon laser 488 nm (40 mW) Em: 500-545 nm; mCitrine, Venus Ex: 
Multi-Line Argon laser 515 nm (40 mW) Em: 530-545 nm; AlexaFluor555 Ex: 559 nm diode laser (20 
mW) Em: 570-625 nm; mCherry Ex: 559 nm diode laser (20 mW) Em: 575-675 nm; AlexaFluor647 Ex: 
635 nm diode laser (20 mW) Em: 655-755 nm. 
 
Time-domain FLIM 
Time-correlated single photon counting measurements to acquire fluorescence lifetime images were 
carried out at room temperature performed using the Fluoview 1000 confocal microscope equipped 
with a FLIM Upgrade Kit (Picoquant). Venus-YFP was excited with a 485 nm diode laser (LDH-D-C-485, 
Picoquant) at 40 MHz repetition, spectrally filtered using a band emission filter (HQ 550/49, AHF, 
Germany) and fluorescence was collected through a silicone immersion oil objective (60X/1.3 
UPLSAPO, Olympus). Photons were detected using a single photon avalanche photodiode (1 channel 
LSM-SPAD, Picoquant) and timed using a single photon counting module (PicoHarp 300, Picoquant). 
FLIM data were background subtracted and processed using the pixel-based fitting software 
SymPhoTime 64 (Picoquant) to calculate the lifetime maps, histograms and average lifetimes of 
Venus-YFP. Goodness of fit was assessed by the calculated standard least squares (χ2) and a mono- or 
bi-exponential fitting model was applied accordingly.  
 
AKAR FRET 
AKAR4-NES is a monomolecular ratiometric FRET sensor containing a PKA substrate site and a FHA1  
phosphoaminoacid binding domain sandwiched between Cerulean CFP donor and cpVenus acceptor 
fluorophores and can thus be used to probe relative PKA activity levels in living cells26,62. Intensity-
based FRET ratio-imaging experiments were performed in HEK293T cells on 24 well plates (µ-plate 
Ibidi) on an inverted epifluorescence IX81 microscope (Olympus) equipped with a MT20 xenon-arc 
burner (Olympus) and an UPLSAPO air 10x/0.4 NA objective controlled by xcellence software 
(Olympus). Images were acquired with a Hamamatsu ImagEM Enhanced EM-CCD camera at a 16-bit 
depth. Donor and FRET-acceptor images were acquired with the following settings: 430/25 
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(excitation), zt442RDC (dichroic mirror) and emission changing between 483/32 (donor-channel) and 
542/27 (FRET-acceptor-channel) using a filter wheel. Images were analysed with ImageJ. Images were 
background corrected and regions of interest were defined using the AKAR4-Venus fluorescence 
channel. Average intensities of the acceptor channel were divided by the donor channel to the 
calculate FRET ratio. 
 
PepTag PKA activity assay 
PepTag Assay (Promega) was carried out as described previously64. Specifically, A1 Peptide (L-R-R-A-
S-L-G) was incubated with or without 25 ng recombinant PKAC (Biovision) together with 10 µM 
scrambled, 36i or PKI(5-24) peptides for 45 min on a shaker at 30°C, before separation of 
phosphorylated and non-phosphorylated peptide by agarose gel (0.8 %) electrophoresis. PKI(5-24) 
peptide for this assay was purchased from Santa Cruz (TTYADFIASGRTGRRNAIHD). 
 
Peptide Synthesis  
Peptides were synthesized on a 433A peptide synthesizer (Applied Biosystems) on Rapp resin 
columns (Rapp Polymere, Tuebingen, Germany) using Fmoc (N-(9-fluorenyl)methoxycarbonyl) 
chemistry. The peptides were purified and analysed by high performance liquid chromatography on 
Polyencap A300 columns (Bischoff, Leonberg, Germany) and electrospray mass spectrometry (TSQ 
700, Finnigan MAT, Bremen, Germany).The sequences of the peptides were 
36i:   E-P-T-L-P-R-E-F-T-R-R-G-R-R-G-A-V-S-V-D-S-L-A-E-L  
Scrambled:  V-R-R-F-P-T-R-A-E-E-T-S-L-E-G-A-G-R-S-R-V-L-L-P-D 
PKI (5-24):          T-T-Y-A-D-F-I-A-S-G-R-T-G-R-R-N-A-I-H-D 
 
Hedgehog Signalling Assay 
NIH3T3 cells seeded on 24-well plates were transfected with 500 ng plasmid for 16 h. The following 
day, the medium was replaced with starvation medium (0.2% FCS) and cells were cultured for further 
48 h. For control experiments shown in Fig. S8h, NIH3T3 cells were cultured for 24 h in the presence 
of 0.2 μM SAG or conditioned medium (collected from HEK293 cells stably secreting SHH-Np (SHHN-
293 cells kindly provided by M. Kato, Stanford School of Medicine) at a 1:10 dilution in medium 
containing 0.5% FCS. RNA was isolated using TRIzol reagent (Life Technologies) and transcribed to 
cDNA using RevertAidFirst Strand cDNA Synthesis Kit (Thermo Scientific). qPCR was performed using 
Maxima SYBR Green qPCR Master Mix (Thermo Scientific) and a Bio-Rad iQ5 Thermal Cycler. cDNA 
was amplified using the following primers: Gli1_fw: CCAGCAGCTGCACTGAAGGATC, 
Gli1_rv: CCAGCTCTGACTTCAGCTGG, mβ-actin_fw: GTCCACACCCGCCACCAGTTC, mβ-actin_rv: 
GGCCTCGTCACCCACATAG 
 
Mass Spectrometry based ubiquitin site identification 
For ubiquitin site identification HEK293T cells were fully labelled in SILAC media, heavy or light, 
before being transiently transfected with PEI. Cells were harvested after 24hours, lysed by sonicating 
in RIPA buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 0.25 % Na-deoxycholate, 1 mM EDTA) 
containing 0.1 % SDS, supplemented with NEM, DNAse and MPI. Lysates were subjected to IP using 
Flag-M2 affinity gel (Sigma). Heavy and light corresponding samples were mixed before the last 
washing step. Proteins eluted in Guanidine-HCl were precipitated in ethanol over night at 4°C as 
previously described65. Proteins were spun down and ethanol decanted. Protein pellet was 
resuspended in 6 M urea and 2 M thiourea in 10mM HEPES (pH 8). Proteins were denatured using 
DTT followed by alkylation of cysteines by chloroacetamide. Proteins were digested by 
endoproteinase LysC and then diluted in 50mM Ammoniumbicarbonate (pH 8) in water before being 
further digested by trypsin over night at room temperature. Resulting peptide solution was desalted 
on stage tips by washing in 5% Acetonitrile and 0.1% formic acid66. Samples were eluted in 80% 
Acetonitrile and 0.1% formic acid and vacuum dried before being diluted in 5% acetonitrile and 0.1% 
formic acid. The peptides were separated on a 15cm column packed in house with ReproSil-Pur 120 
C18-AQ 3µm resin (Dr. Maisch GmbH), using a 1h linear gradient of increasing acetonitrile 
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concentration with a flow rate of 250 nL/min on a high pressure liquid chromatography (HPLC) 
system (ThermoScientific). Separated peptides were ionized using an electrospray ionization source 
(ThermoScientific) and analyzed on Q Exactive mass spectrometer (ThermoScientific). The Orbitrap 
resolution was set to 70,000 (target value 3,000,000; maximum injection time of 20 ms) for full scans 
and 17,500 (maximum injection time 60 ms; target value 1,000,000) for MS/MS spectra. The system 
was run in a data dependent mode selecting the top 10 most intense ions for higher energy collision 
induced dissociation.   
Raw files were analyzed using the MaxQuant software 1.5.1.167 using the default setting but with 
‘Requantify’ and ‘match between runs’ activated. Lys8 and Arg10 were set as the heavy label. 
Ubiquitin leaves a signature GlyGly modification of Lysines (+114.0429 Da) after tryptic digestion. The 
GlyGly(K) modification, acetylation of protein N-termini and oxidation of methionine were set as 
variable modifications. C-terminal carbamidomethylation was set as a fixed modification. Trypsin/P 
was set as protease for the in silico digest of the Human Uniprot database (2014-01) in addition to a 
data base containing common contaminants. The false discovery rate was set to 1% both at the 
peptide and protein level and was estimated by in parallel matching the MS/MS spectra against a 
database containing the reversed sequences of the Uniprot database67. 
Plotting of the SILAC ratios was done using R version 2.15.1 (R Foundation for Statistical Computing, 
Vienna, Austria) and Spectra were visualized by the MaxQuant viewer. Both figures were modified in 
Illustrator (Adobe). 
 
SRM chain linkage identification 
For SRM chain linkage identification HEK293T cells were lysed as described, and subjected to IP using 
GFP-Trap Beads (Chromotek) before washing with 2M Guanidine-HCl followed by water and eluting 
in 2x SDS sample buffer. Eluates were run briefly on an SDS-PAGE gel followed by an in-gel digestion 
with trypsin. After a solid-phase extraction and desalting, peptides were eluted, lyophilized and 
reconstituted with a 0.1% formic acid/3% ACN buffer containing 100 fmol/L of  heavy tryptic 
peptide standards corresponding to all the different polyubiquitin linkage types34. Peptides were 
separated on a reversed-phase column (20 cm length, 75 m ID, 3 m Dr. Maisch C18) with a 
gradient from 3 to 36% ACN in 38 min and SRM measurements performed using a Q-Trap 6500 (AB 
Sciex). The top two most intense transitions were selected and their peaks integrated with 
MultiQuant 3.0 software (AB Sciex). In parallel, the samples were measured in data-dependent 
acquisition mode using an Orbitrap Q-Exactive instrument (Thermo) with an on-line chromatography 
equivalent to what was described for the SRM analysis.  The raw files were analyzed with MaxQuant 
1.5.2.8 and the signal intensity for PKAC used to normalize the SRM-MS data to account for variation 
between the IPs. 
 
Global protein abundance measurements (iBAQ) 
For iBAQ NGP cells were harvested, pelleted and flash-frozen prior to precipitation of proteins with 
equal volumes of chloroform, methanol and water68. Proteins were solubilized in 6M urea/2M 
thiourea buffer containing 10 mM HEPES and treated with benzonase to digest DNA and reduce 
viscosity. 50 µg lysate was subjected to reduction with TCEP (tris(2-carboxyethyl)phosphine) and 
alkylation with CAA (2-chloroacetamide) before digestion with trypsin. Peptides were extracted and 
desalted with a C18 StageTip prior to elution and reconstitution in 3% ACN/0.1% formic 
acid, followed by separation on a reversed-phase column (20 cm length, 75 m ID, 3m Dr. Maisch 
C18) with a gradient from 5 to 45 % ACN in 120 min, while MS and MS/MS spectra were acquired in 
data-dependent mode on a Q-Exactive Plus interment (Thermo).  Raw data files were analyzed with 
MaxQuant 1.5.2.8.  
To calculate protein abundances we applied the ‘intensity based absolute quantification’ algorithm 
[iBAQ29]. In short, we first calculated the number of theoretically observable peptides per protein by 
in silico trypsin-digesting the Uniprot data base. We then divided the protein intensities by the 
theoretical observable peptide count.  
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ITC measurements 
Peptide stock solutions were prepared in the same buffer used for the final purification step of His-
PKAC (50 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl2) as detailed in the Supplemental Methods. 
Peptide concentration of PKI and 36i were determined with the Direct Detect™ Spectrophotometer 
(EMD Millipore). Quantification by absorbance at 280 nm was not possible as 36i does not contain 
tyrosine or tryptophan residues. Peptide concentrations were determined from triplicate 
measurements using 2 µL of diluted (ca. 2 mg/mL) peptide solution with the above mentioned buffer 
used as a blank. ITC data were acquired on a microcalorimeter VP-ITC (MicroCal Inc). Stock solutions 
of PKAC, PKI and 36i were dissolved in 50 mM HEPES, pH 7.5 containing 150 mM NaCl, 5 mM MgCl2 
and 2 mM AMPPNP. Titrations were conducted at 25 °C using 30 µM PKAC and 507 µM PKI or 351 
µM 36i, respectively. Samples were stirred at 351 rpm. Injections were separated by 280 s of 
equilibration. A one-site binding model was assumed and the data were fitted using Microcal Origin 
software (version 7.0). 
 
Image Analysis 
Line scans to determine fluorescence intensity profiles were analysed using ImageJ software. Briefly, 
Plot Profile analysis was used to create a graph of pixel intensity plotted against the distance along 
the line. To reduce noise, pixel intensity was averaged on a line width of 10 pixels. Intensity was then 
normalized to the lowest and the highest intensity within the selection. For analysis of protein level 
ratios of ARHGAP36 and PKAC in immunofluorescence images of NGP cells, automated cell 
segmentation was performed with CellProfiler software69 based on DAPI, CellTracker Deep Red and 
ARHGAP36 images. Average PKAC and ARHGAP36 intensities were measured in each cell outline. 
Each single cell intensity was normalised to the median intensity of all cells in each image. Pearson’s 
sample correlation analysis was performed in OriginPro (OriginLab). 
 
Statistics 
An unpaired Student’s T-test was used to evaluate statistical significance were required. Values are 
expressed as the mean ± s.e.m. or s.d. as indicated. Significance was set at the 95% confidence level 
and ranked as * p<0.05, ** p<0.01, *** p<0.001. 
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Supplemental Information includes Supplemental Methods and nine figures. 
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FIGURE LEGENDS 
Figure 1. ARHGAP36 interacts with PKAC (a) Schematic representation of human ARHGAP36 isoform 
2 (UniProt ID: Q6ZRI8-2). (b) Left panel: HEK293T cells were transfected with PKAC-YFP and Flag-
ARHGAP36 or Flag-Cherry control. Lysates were immunoprecipitated using a Flag antibody, and 
immunoblotted with GFP or Flag antibodies. Right panel: HEK293T cells were transfected with YFP-
ARHGAP36 or YFP-Cherry control. Lysates were immunoprecipitated using a GFP antibody, and 
immunoblotted with GFP or PKAC antibodies. Note the reduction of PKAC in presence of ARHGAP36. 
(c) Confocal live micrographs of MDCK cells expressing CFP-ARHGAP36 and PKAC-YFP, either alone or 
together. (d) FLIM-FRET measurements in MDCK cells expressing PKAC-YFP (donor) either alone, or 
together with mCherry-ARHGAP36 (acceptor) before and after acceptor photobleaching. Shown are 
YFP and mCherry confocal images and pseudocoloured donor fluorescence lifetime maps. Right 
panel: Corresponding histograms of the prebleach (red) and postbleach (blue) lifetime values 
together with the donor only control sample (black).  
Figure 2. ARHGAP36 interacts with PKAC via a pseudosubstrate domain (a) HEK293T cells were 
transfected with PKAC-YFP together with Flag-tagged wild-type ARHGAP36 (WT), 195-516 (N), 1-
194 (N) or Flag-Cherry control. Lysates were immunoprecipitated using a GFP antibody, and 
immunoblotted with GFP or Flag antibodies. (b) Confocal live micrographs of MDCK cells expressing 
PKAC-YFP together with CFP-N, CFP-N or CFP-N2 (118-194). Nuclear enrichment of ARHGAP36-N2, 
bottom left, may be facilitated by the arginine rich sequence. Scale Bars: 10 m. (c) Immobilized 
peptide ‘spots’, overlapping 25-mer peptides each shifted along by five amino acids in the entire 
ARHGAP36 sequence, were probed for interaction with GST-PKAC and immunoblotted using a GST 
antibody. The sequence of the spot with strongest interaction is shown. (d) Alanine and Aspartate 
scans of the spot indicated in (c) were treated the same as in (c). Asterisk indicates wildtype 
sequence spot. (e) Alignment of human ARHGAP36 with the human isoforms of PRKAR and PKI 
revealing its pseudosubstrate motif RRxAY. (f) Confocal live micrographs of MDCK cells coexpressing 
CFP-ARHGAP36-RRV and PKAC-YFP. Scale Bars: 10 m. (g) Average YFP fluorescence lifetimes of 
MDCK cells expressing PKAC-YFP alone or together with mCherry-ARHGAP36, -N or -RRV, or PKAC-
EEE-YFP (E127A/E170A/E230A) together with mCherry-ARHGAP36 (n≥4 each). Error bars denote 
mean ± s.d., statistics versus PKAC-YFP donor alone. (h) ITC measurements were performed in the 
presence of 2 mM AMPPNP. 30 µM His-PKAC solution (cell) was titrated with 507 µM PKI or 351 µM 
36i (syringe) until saturation was reached using 8 µL or 6 µL injections, respectively (the first injection 
was always carried out with half the volume and omitted from data analysis). 36i and PKI bound to 
PKAC●AMPPNP with almost identical affinities. The measured values are in a similar range as 
previously reported for the PKAC-PKI interaction in the presence of other ATP analogues or ADP70. 
Figure 3. ARHGAP36 inhibits PKAC (a) Recombinant PKAC (25 ng) was incubated with 10 M 
scrambled, 36i or PKI peptide, and its activity determined by its ability to phosphorylate the substrate 
peptide PepTag A1. Phosphorylated and non-phosphorylated peptide were separated by agarose 
electrophoresis, and densitometrically analysed. Representative gel shown. Recombinant PKAC 
activity is shown as the ratio of phosphorylated to non-phosphorylated peptide (mean of eight 
repeats +/- SEM, *** p<0.001 versus all three controls).  (b) AKAR4-NES FRET sensor was expressed 
together with Cherry control, Cherry-ARHGAP36 (WT), the indicated mutants or 36i-Cherry or PKI-
Cherry in HEK293T cells. Cells were serum starved for five hours, treated with 10 µM Forskolin and 
100 µM IBMX for 30 min and subsequently imaged. Mean FRET emission ratio (acceptor 
intensity/donor intensity) of three independent experiments normalised to control +/- s.d. *** 
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p<0.001, n.s. not significant versus control and RRV. (c) Representative images of HEK293T cells 
expressing  AKAR4-NES FRET sensor together with Cherry control, Cherry-ARHGAP36 (WT) or Cherry-
ARHGAP36-RRV. Cells were treated as in (b). Shown are YFP intensity images and pseudocoloured 
FRET ratio images (acceptor intensity/donor intensity) reflecting the relative PKA activity levels. Scale 
bars: 100 µm. The histograms show the pixel distribution within the FRET emission ratio images. 
Figure 4. ARHGAP36 downregulates PKAC levels (a) MDCK cells transfected with YFP-ARHGAP36, or 
a YFP control, were fixed after 8 or 24 hours and subjected to immunofluorescence using antibodies 
against GFP and PKAC. Images were collected by confocal microscopy. Scale bars: 10 m. (b) 
HEK293T cells were transfected with YFP-ARHGAP36 or YFP-Cherry control for 24 hours. Lysates were 
immunoblotted with the indicated antibodies. (c) HEK293T cells were transfected with YFP-
ARHGAP36 or YFP control. Lysates were immunoblotted with antibodies against RIa, RIb RIIa, RIIb, 
GAPDH and GFP. (d) MDCK cells transfected with CFP-PKI were fixed after 24 hours and subjected to 
immunofluorescence as in (a). Scale bar: 10 m. (e) MDCK cells transfected with YFP-ΔN (195-516), 
YFP-N (1-194), YFP-N2 (118-195), YFP-RRV or Cherry-36i were fixed after 24 hours and subjected to 
immunofluorescence as in (a). 36i signal was not amplified using antibodies. Scale bars: 10 m. 
Figure 5. ARHGAP36 targets PKAC for lysosomal degradation (a) HEK293T cells were transfected 
with PKAC-Flag and YFP-ARHGAP36 or YFP-Cherry control as indicated. Before harvesting cells were 
pre-treated for 30 minutes with, epoxomicin (50 nM) or bafilomycin (100 nM), before cycloheximide 
(CHX) (50 µg/ml) addition for a further six hours. Lysates were immunoblotted with the indicated 
antibodies. Flag-PKAC levels were densitometrically evaluated and normalised to the first lane 
shown. (b) MDCK cells were transfected with YFP-ARHGAP36 or YFP control for eight hours and, 
where indicated, were pre-treated for 30 minutes with epoxomycin (100 nM) or bafilomycin (100 
nM), before cycloheximide (1 µg/ml) addition for a further eight hours. Cells were then fixed after a 
total of 16 hours transfection and subjected to immunofluorescence using antibodies against GFP 
and PKAC. Images were collected by confocal microscopy. Scale bars: 10 m. Graph shows the 
percentage of YFP-ARHGAP36 transfected cells with the respective phenotype, 100 cells counted per 
condition. (c) Confocal micrographs of MDCK cells transfected with Flag-ARHGAP36 together with 
GFP-HRS, LAMP1-YFP or GFP-Rab5-QL. Cells were fixed and subjected to immunofluorescence using 
antibodies against GFP, Flag and PKAC. Scale bars: 10 m. For Rab5-QL, line scan fluorescence 
intensity profiles are shown on the right. In red: Rab5-QL, in blue: PKAC. (d) Confocal micrographs of 
U2OS cells transfected with PKAC-YFP and Flag-ARHGAP36. Cells were fixed and subjected to 
immunofluorescence using antibodies against GFP, Flag, EEA-1 and HRS. Scale bars: 10 m. 
Figure 6. ARHGAP36 induces PKAC ubiquitylation and engagement with the ESCRT pathway (a) 
HEK293T cells were transfected with PKAC-YFP or YFP-Cherry control, Flag-ARHGAP36 and His-
Ubiquitin as indicated. Lysates were subjected to GFP IP. (b) SILAC-labelled HEK293T cells were 
transfected with PKAC-Flag in the presence or absence of YFP-ARHGAP36. Lysates were subjected to 
Flag IP. Heavy/Light-ratio plot of the normalised peptide evidences matching PRKAC. Only one 
peptide, highlighted in red, was upregulated in the presence of ARHGAP36 and was the only 
ubiquitylated PRKACA peptide identified. (c) The same as in (a) except where indicated PKAC-K285R-
YFP was transfected. (d) The same as in (c) except lysates were subjected to His IP and 
immunoblotted with anti-GFP. (e) HEK293T cells were transfected with PKAC-Flag and CFP-
ARHGAP36, the RRV mutant or CFP-Cherry control. Lysates were immunoblotted with the indicated 
antibodies. (f) Confocal micrographs of MDCK cells transfected with PKAC-YFP or PKAC-K285R-YFP 
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and Flag-ARHGAP36. 12 hours after transfection, cells were pre-treated for 30 minutes with 
bafilomycin (100 nM), before cycloheximide (1 µg/ml) addition for a further five hours. Cells were 
fixed and subjected to immunofluorescence using anti-GFP and anti-Flag. Scale bars: 10 m. (g)   
HEK293T cells were transfected with PKAC-YFP in the presence or absence of Flag-ARHGAP36 and 
subjected to GFP IP followed by SRM-MS based relative quantitation of polyubiquitin linkage-type 
peptides. Data was normalised using the signal intensity of PKAC derived from a shotgun MS analysis 
of the same samples. Samples were measured in duplicate and the top two transitions used for 
quantitation. The error bars represent the standard deviation of the four calculated area ratios. (h) 
HEK293T cells were transfected with GFP-Vps4-WT or GFP-Vps4-EQ, PKAC-Flag and Cherry-
ARHGAP36 or Cherry control as indicated. Cells were treated with cycloheximide (50 µg/ml) and 
harvested at the indicated time points. Flag-PKAC levels were densitometrically evaluated and 
normalised to the first lane shown. 
Figure 7. ARHGAP36 suppresses PKA signalling (a) MDCK cells expressing YFP-ARHGAP36 or YFP 
control in low serum conditions were treated with 10 M Forskolin and 100 M IBMX for 20 minutes, 
fixed and subjected to immunofluorescence using antibodies against GFP and phospho-CREB. Images 
were collected by confocal microscopy. Scale bars: 10 m. Right panel: Quantitative analysis of 
nuclear phospho-CREB staining in cells expressing the indicated constructs (n>100 for each of three 
independent experiments, shown as mean ±SEM,*** p<0.001). (b) As in (a) except cells were 
transfected with Cherry-36i, CFP-PKI or CFP-ARHGAP36-RRV. (c) MCD4 cells stably expressing 
Aquaporin2 (AQP2) were transfected with YFP-ARHGAP36 or YFP control in low serum conditions. 24 
hours post-transfection, cells were treated with 10 M Forskolin for 20 minutes. Fixed cells were 
subjected to immunofluorescence using antibodies against GFP, AQP2 and the tight junction protein 
ZO-1, to visualise the plasma membrane at cell-cell contact sites. Images were collected by confocal 
microscopy. Scale bars: 10 m. Line scan fluorescence intensity profiles are shown on the right. In 
red: AQP2, in blue: ZO-1.  
Figure 8. ARHGAP36 is expressed in neuroblastoma cells and promotes aberrant activation of the 
Hedgehog pathway (a) 10 g lysate of the indicated cell lines were immunoblotted with the 
indicated antibodies. ARHGAP36 expression is only present in NGP and CLB-GA neuroblastoma cells. 
The predominant isoform seems to be isoform 3, expected size 46 kDa. (b) Left: Histogram displaying 
the distribution of the relative abundance of all measured proteins. ARHGAP36 and PKAC are found 
within the same bin (pink). Right: Bar plot of log 10 abundance of the indicated proteins relative to 
ARHGAP36. GAPDH and PKAC are expressed in a 437 fold and 0.95 fold abundance relative to 
ARHGAP36, respectively. PKAC is the summed total of PRKACA and PRKACB.  (c) NGP cell lysates were 
immunoprecipitated with an ARHGAP36 antibody or IgG rabbit control, and immunoblotted for 
ARHGAP36 or PKAC. (d) Confocal micrographs of NGP or CLB-GA cells transfected with GFP-Rab5-QL. 
Cells were fixed and subjected to immunofluorescence using antibodies against GFP, ARHGAP36 and 
PKAC. Scale bar: 5 m. (e) Representative immunoblot of NGP cells treated with an siRNA 
SMARTpool against ARHGAP36 (si36) for 24 hours. Cells were stimulated with 10 M Forskolin and 
100 M IBMX before harvesting. Lysates were immunoblotted with the indicated antibodies. Lipo: 
reagent only control. NT1: non-targeting oligo control. Bands were densitometrically evaluated, 
normalised first to tubulin then to Lipo. Mean of five independent experiments +/- s.d. ** p<0.01 
compared to NT1. (f) Representative immunoblot of CLB-GA cells treated with individual or 
combined siRNA oligos against ARHGAP36 for 48 hours. Lysates were immunoblotted with the 
indicated antibodies. Lipo: reagent only control. NT1: non-targeting oligo control. Bands were 
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densitometrically evaluated, normalised first to tubulin then to Lipo. Mean of four independent 
experiments +/- s.d. ** p<0.01 or * p<0.05 compared to NT1. (g) Confocal micrographs of NGP cells 
subjected to immunofluorescence using antibodies against ARHGAP36 and PKAC. Scale bar: 10 m. 
(h)  NIH3T3 cells transfected with the indicated CFP-tagged constructs for 15 hours were serum 
starved for a further 48 hours before harvesting. Gli1 mRNA was measured by quantitative RT-PCR 
and levels normalized to β-actin. Data shown as mean of three repeats +/- SEM, *** p<0.001 
compared to control (i) As in (h), except cells were transfected with CFP-PKI.  
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